The SINDAS trial provided high level evidence that upfront ablative radiation to all sites of oligometastatic EGFR-mutant non-small cell lung cancer (NSCLC) prolongs survival. Both prospective and retrospective studies in this space have consistently demonstrated blockbuster successes with this approach, specifically for NSCLC histologies. But don’t take our word for it—this metaanalysis aims to quantify the sweeping data out there on local therapy for metastatic NSCLC. Across 693 subjects of 7 studies (4 prospective randomized and 3 retrospective propensity-matched), local consolidative therapy slashed risk of progression or death (HR 0.36) and even halved overall deaths (HR 0.51). Importantly in the context of SINDAS, these advantages remained rock solid when stratifying by EGFR-status. Finally, as expected, local therapy did not increase grade 3+ toxicity. | Wu, Int J Radiat Oncol Biol Phys 2022


Popular Posts